Hemab Therapeutics Holdings, Inc. (COAG) stock
COAGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$39.86+0.71 (+1.81%)
Close on Nov 19, 2026Market cap $1.86BP/E –Yield –
Hemab Therapeutics net income
Net income is the profit left for shareholders after every expense, interest and tax.
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$27.30M | – |
| Q2 FY2026 | Jun 30, 2026 | -$24.15M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.69M | – |
| Q3 FY2025 | Sep 30, 2025 | -$17.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.21M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.31M | – |
See a number that looks wrong?